Log in
NASDAQ:ATOS

Atossa Genetics Stock Forecast, Price & News

$1.49
-0.06 (-3.87 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.46
Now: $1.49▼
$1.60
50-Day Range
$1.55
MA: $2.18▼
$2.52
52-Week Range
$0.76
Now: $1.49▼
$5.08
Volume117,903 shs
Average Volume151,423 shs
Market Capitalization$15.50 million
P/E RatioN/A
Dividend YieldN/A
Beta2.27
Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.
Read More
Atossa Genetics logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.18 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ATOS
Previous Symbol
CUSIPN/A
CIK1488039
Webwww.atossagenetics.com
Phone206-325-6086
Employees4

Debt

Debt-to-Equity RatioN/A
Current Ratio5.51
Quick Ratio5.51

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.37 per share
Price / Book1.09

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-17,240,000.00
Net MarginsN/A
Return on Equity-113.89%
Return on Assets-96.09%

Miscellaneous

Outstanding Shares10,400,000
Market Cap$15.50 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
$1.49
-0.06 (-3.87 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATOS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Atossa Genetics (NASDAQ:ATOS) Frequently Asked Questions

How has Atossa Genetics' stock been impacted by COVID-19 (Coronavirus)?

Atossa Genetics' stock was trading at $0.88 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ATOS shares have increased by 69.3% and is now trading at $1.49.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Atossa Genetics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atossa Genetics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Atossa Genetics.

When is Atossa Genetics' next earnings date?

Atossa Genetics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Atossa Genetics.

How were Atossa Genetics' earnings last quarter?

Atossa Genetics Inc (NASDAQ:ATOS) announced its earnings results on Thursday, August, 13th. The company reported ($0.43) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.15.
View Atossa Genetics' earnings history.

When did Atossa Genetics' stock split? How did Atossa Genetics' stock split work?

Shares of Atossa Genetics reverse split on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 19th 2018. An investor that had 100 shares of Atossa Genetics stock prior to the reverse split would have 8 shares after the split.

What price target have analysts set for ATOS?

2 brokers have issued 12 month price objectives for Atossa Genetics' shares. Their forecasts range from $7.00 to $8.00. On average, they anticipate Atossa Genetics' share price to reach $7.50 in the next twelve months. This suggests a possible upside of 403.4% from the stock's current price.
View analysts' price targets for Atossa Genetics.

Are investors shorting Atossa Genetics?

Atossa Genetics saw a drop in short interest in the month of October. As of October 15th, there was short interest totaling 172,700 shares, a drop of 15.2% from the September 30th total of 203,600 shares. Based on an average daily volume of 458,600 shares, the days-to-cover ratio is currently 0.4 days.
View Atossa Genetics' Short Interest.

Who are some of Atossa Genetics' key competitors?

Some companies that are related to Atossa Genetics include Satsuma Pharmaceuticals (STSA), Infinity Pharmaceuticals (INFI), Addex Therapeutics (ADXN), AgeX Therapeutics (AGE), Rockwell Medical (RMTI), Predictive Technology Group (PRED), Oramed Pharmaceuticals (ORMP), Mereo BioPharma Group (MREO), Trevi Therapeutics (TRVI), Appili Therapeutics (APLIF), Entasis Therapeutics (ETTX), Edesa Biotech (EDSA), Aerpio Pharmaceuticals (ARPO), Aerpio Pharmaceuticals (ARPO) and Savara (SVRA).
View all competitors.

What other stocks do shareholders of Atossa Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Genetics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Heat Biologics (HTBX), Vaxart (VXRT), Biocept (BIOC), MannKind (MNKD), Biopharmx (BPMX), Dare Bioscience (DARE), Opko Health (OPK) and Nokia (NOK).

Who are Atossa Genetics' key executives?

Atossa Genetics' management team includes the following people:
  • Dr. Steven C. Quay, Chairman, CEO & Pres (Age 68)
  • Mr. Kyle Guse CPA, Esq., CPA, CFO, Gen. Counsel & Sec. (Age 55)
  • Ms. Janet Rose Rea, Sr. VP of Regulatory, Quality & Clinical Affairs
  • Dr. Jack Cuzick, Member of Scientific Advisory Board

What is Atossa Genetics' stock symbol?

Atossa Genetics trades on the NASDAQ under the ticker symbol "ATOS."

How do I buy shares of Atossa Genetics?

Shares of ATOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Atossa Genetics' stock price today?

One share of ATOS stock can currently be purchased for approximately $1.49.

How big of a company is Atossa Genetics?

Atossa Genetics has a market capitalization of $15.50 million. Atossa Genetics employs 4 workers across the globe.

What is Atossa Genetics' official website?

The official website for Atossa Genetics is www.atossagenetics.com.

How can I contact Atossa Genetics?

Atossa Genetics' mailing address is 107 SPRING STREET, SEATTLE WA, 98104. The company can be reached via phone at 206-325-6086 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.